In order to sustain the market growth and to increase the use of proton therapy as an efficient cancer treatment, the PT industry will need to better involve the medical community with stronger marketing to grow the referencing of patients toward proton therapy centers. We see some mixed signals from the proton therapy area, such as the medical-scientific community stating that at least 10% of the population requiring external radiotherapy treatment would benefit from proton therapy. However, this level was only at 0.6% in 2016 and almost all operational PT centers are far to be at capacity. To date, PT center operators face apparent difficulties in recruiting annually a sufficient number of patients. Only 13% of the operational PT facilities were able to treat on average over 200 patients per treatment room in 2016 and only two PT facilities were able to treat more than 300 patients per treatment room.

With the entrance of Varian in 2007 in the proton therapy market, the emergence of new vendors, the recent introduction of lower-cost/compact systems, and, more importantly, with the growing clinical evidence regarding the efficacy of particle therapy that will progressively be used to treat a broader number of indications, there is room for a further acceleration of the market, especially if the industry initiates the development of novel equipment, lighter and less expensive.


All these data are extensively detailed in the new Proton Therapy World Market Report & Directory, Edition 2018, a 340-page document featuring a comprehensive review of the world market dynamics with an analysis of both past evolutions and future trends to the year 2030.

About MEDraysintell
MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, with over 2,100 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare.

Back to HCB News

Rad Oncology Homepage